Madison, N.J., May 25, 2006 – Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), this week presented for the first time phase 3 data and results from other studies concerning its investigational ...

Pfizer Reports Top Line Results from a Phase 3 Study Evaluating Desvenlafaxine Succinate Sustained-Release Formulation in Pediatric Patients with Major Depressive Disorder June 11, 2015 - Pfizer Inc ...

Findings from two separate pooled analyses - one examining the effect of desvenlafaxine succinate on anxious symptoms and the other on painful symptoms associated with major depressive disorder (MDD) ...

COLLEGEVILLE, Pa., Oct. 15 -- Wyeth Pharmaceuticals, a division of Wyeth , reported that new study data presented today at the 63rd Annual Meeting of the American Society for Reproductive Medicine ...

DailyUpdates 26th May, 2006: As our daily trip around the drug discovery world continues we hit Friday with some revealing information on sepsis and new phase 3 data on Wyeth's antidepressant ...

September 20, 2011 — The US Food and Drug Administration (FDA) has denied an application for use of the dual serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate (Pristiq ...

Alembic Pharma had received approval of its ANDA of desvenlafaxine succinate extended release tablets of strengths 50 mg and 100 mg in June 2015. Advisory Alert: It has come to our attention that ...

Updates - Alembic Pharmaceuticals Limited announces launch of desvenlafaxine succinate extended release tablets by its partnerSource : BSE Advisory Alert: It has come to our attention that certain ...

London, 10 March 2017 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, ...

SAN FRANCISCO (MarketWatch) -- Wyeth on Tuesday said the Food and Drug Administration has extended the action date by three months to Jan.22 for its review of a new drug application for desvenlafaxine ...

restless. Should these occur, report them to a doctor right away. PRISTIQ is not approved for use in children under 18. Do not take PRISTIQ if you are allergic to desvenlafaxine, venlafaxine, or any ...